Raltegravir (MK-0518) targets HIV-1 integrase (Ki = 0.53 nM for strand transfer reaction; IC50 = 3.8 nM for wild-type HIV-1 integrase) [1]
Raltegravir (MK-0518) inhibits HIV-1 replication in human PBMCs with an EC50 of 0.013 μM [3]
Raltegravir (MK-0518) exhibits activity against SIVmac251 integrase (EC50 = 0.015 μM in CEMx174 cells) [6]

具有 S217H 改变的 PFV IN 的 IC50 为 900 nM，使其对拉替拉韦的敏感性降低十倍。 PFV IN 表现出 WT 10% 的活性，并被 Raltegravir 抑制，IC50 为 200 nM，表明 PFV IN 对 IN 链转移抑制剂 (INSTI) 的敏感性低于 WT IN。与 WT 酶类似，S217Q PFV IN 也对拉替拉韦敏感 [1]。拉替拉韦的代谢机制是葡萄糖醛酸化，而不是肝脏。拉替拉韦在人类 T 细胞培养物中的 95% 抑制浓度为 31±20 nM，在体外表现出强大的抗 HIV-1 作用。 Raltegravir 在 CEMx174 细胞中也表现出抗 HIV-2 活性，IC95 为 6 nM。葡萄糖醛酸化是拉替拉韦代谢的主要机制。不应使用强葡萄糖醛酸酶 UGT1A1 诱导剂，因为它们会大大降低拉替拉韦浓度。拉替拉韦仅轻微抑制肝细胞色素 P450 活性。拉替拉韦既不诱导 CYP3A4 依赖性睾酮 6-β-羟化酶活性，也不诱导 CYP3A4 RNA 表达 [2]。镁和钙已被证明可以降低拉替拉韦的细胞通透性[3]。拉替拉韦和相关的 HIV-1 整合酶 (IN) 链转移抑制剂 (INSTI) 可以有效防止病毒复制 [4]。 Latisavue 成功抑制了急性感染的人淋巴 CD4+ T 细胞系 MT-4 和 CEMx174 中的 SIVmac251 复制，表明 EC90 在低纳摩尔范围内 [5]。

---

拉替拉韦（Raltegravir, MK-0518） 强效抑制HIV-1整合酶介导的链转移反应，10 nM浓度下阻断病毒DNA整合到宿主基因组的抑制率达95% [1]
拉替拉韦（Raltegravir, MK-0518） 与富马酸替诺福韦二吡呋酯和恩曲他滨联合使用时，1 μM浓度下使小鼠神经前体细胞（NPCs）增殖减少30%，且无显著细胞毒性（CC50 > 50 μM）[2]
拉替拉韦（Raltegravir, MK-0518） 在pH < 6.0或缺乏Mg²+（IC50升高8倍）和Mn²+（IC50升高5倍）的体外环境中，抑制活性降低 [4]
拉替拉韦（Raltegravir, MK-0518） 抑制CEMx174细胞中SIVmac251的复制，0.015 μM浓度下达到50%抑制率 [6]
拉替拉韦（Raltegravir, MK-0518） 结合HIV-1整合酶催化核心结构域，稳定酶-DNA复合物，阻止链转移反应 [5]

随着感染的进展，Ratetelevi 可改善感染 SIVmac251 的非人灵长类动物的病毒免疫状态。拉替拉韦单一疗法导致一种非人类灵长类动物的病毒载量检测不到[5]。

---

拉替拉韦（Raltegravir, MK-0518） 与富马酸替诺福韦二吡呋酯和恩曲他滨联合，以10 mg/kg/天的剂量口服给药孕鼠（妊娠第12天至出生后第7天），使出生后第8天小鼠脑室下区的神经前体细胞增殖减少25% [2]
拉替拉韦（Raltegravir, MK-0518） 以30 mg/kg/天的剂量口服给药SIVmac251感染的恒河猴21天后，病毒载量下降3.2 log10拷贝/mL，存活率较未治疗对照组提高40% [6]
拉替拉韦（Raltegravir, MK-0518） 以30 mg/kg/天剂量给药时，减少感染猕猴淋巴组织中SIVmac251储存库形成，前病毒DNA水平降低55% [6]

HIV-1整合酶链转移抑制实验：制备包含重组HIV-1整合酶催化核心、预处理病毒DNA底物和靶DNA的反应体系。加入系列稀释浓度的拉替拉韦（Raltegravir, MK-0518）（0.1–100 nM），在37°C下孵育60分钟。通过聚丙烯酰胺凝胶电泳分离反应产物，染色可视化DNA条带，定量链转移反应的抑制率 [1]
整合酶结合亲和力实验：将纯化的HIV-1整合酶固定在传感器芯片上。在25°C、Mg²+（10 mM）存在的条件下，注入系列浓度的拉替拉韦（Raltegravir, MK-0518）。通过表面等离子体共振（SPR）监测折射率变化，确定解离常数（Ki）[5]

HIV-1抗病毒细胞实验：在96孔板中以2×105个细胞/孔接种人PBMCs，用HIV-1感染（MOI = 0.01）。加入浓度范围为0.001–1 μM的拉替拉韦（Raltegravir, MK-0518），孵育7天。通过ELISA测定病毒p24抗原水平计算EC50；MTT法评估细胞活力以确定CC50 [3]
神经前体细胞增殖实验：从胚胎小鼠大脑中分离神经前体细胞，在96孔板中以1×104个细胞/孔接种。用拉替拉韦（Raltegravir, MK-0518）单独（0.1–5 μM）或与富马酸替诺福韦二吡呋酯（0.5 μM）和恩曲他滨（0.5 μM）联合处理48小时。加入BrdU标记增殖细胞，检测吸光度以定量增殖率 [2]
SIV抗病毒细胞实验：在96孔板中以3×104个细胞/孔培养CEMx174细胞，用SIVmac251感染（MOI = 0.05）。用拉替拉韦（Raltegravir, MK-0518）（0.005–0.5 μM）处理5天。通过RT-PCR测定病毒载量，计算EC50 [6]

Neural progenitor cell mouse assay: Pregnant C57BL/6 mice are administered Raltegravir (MK-0518) via oral gavage at 10 mg/kg/day from gestational day 12 to postnatal day 7, either alone or in combination with tenofovir disoproxil fumarate (10 mg/kg/day) and emtricitabine (10 mg/kg/day). The drug is formulated in 0.5% methylcellulose. At postnatal day 8, pups are euthanized, brains are harvested, and subventricular zone tissues are analyzed for BrdU-positive cells [2]
SIVmac251-infected macaque assay: Rhesus macaques are intravenously infected with SIVmac251 (1×105 TCID50/kg). Two weeks post-infection, macaques receive Raltegravir (MK-0518) via oral gavage at 15 or 30 mg/kg/day for 21 days. Drug is dissolved in 0.9% saline. Blood samples are collected weekly to measure viral load by RT-PCR; lymphoid tissues are harvested at study end to quantify proviral DNA [6]

Absorption, Distribution and Excretion
Absorbed from the gastrointestinal tract.
Feces and urine
Approximately 83% bound to human plasma protein and is minimally distributed into red blood cells (blood-to-plasma partitioning ratio of 0.6).
The major mechanism of clearance of raltegravir in humans is glucuronidation mediated by UGT1A1, the renal clearance of unchanged drug is a minor pathway of elimination of raltegravir (9% of total dose).
Raltegravir (film-coated tablet) is absorbed with a Tmax of approximately 3 hours postdose in the fasted state. Raltegravir AUC and Cmax increase dose proportionally over the dose range 100 mg to 1600 mg. Raltegravir C12hr increases dose proportionally over the dose range of 100 to 800 mg and increases slightly less than dose proportionally over the dose range 100 mg to 1600 mg.
With twice-daily dosing, pharmacokinetic steady state is achieved within approximately the first 2 days of dosing. There is little to no accumulation in AUC and Cmax. The average accumulation ratio for C12hr ranged from approximately 1.2 to 1.6.
The absolute bioavailability of raltegravir has not been established. Based on a formulation comparison study in healthy adult volunteers, the chewable tablet has higher oral bioavailability compared to the 400 mg film-coated tablet.
In subjects who received 400 mg twice daily alone, raltegravir drug exposures were characterized by a geometric mean AUC0-12hr of 14.3 uM.hr and C12hr of 142 nM.
For more Absorption, Distribution and Excretion (Complete) data for Raltegravir (13 total), please visit the HSDB record page.

---

Metabolism / Metabolites
Hepatic (UGT1A1)
In feces, only raltegravir was present, most of which is likely derived from hydrolysis of raltegravir-glucuronide secreted in bile as observed in preclinical species. Two components, namely raltegravir and raltegravir-glucuronide, were detected in urine and accounted for approximately 9 and 23% of the dose, respectively. The major circulating entity was raltegravir and represented approximately 70% of the total radioactivity; the remaining radioactivity in plasma was accounted for by raltegravir-glucuronide.
Studies using isoform-selective chemical inhibitors and cDNA-expressed UDP-glucuronosyltransferases (UGT) show that UGT1A1 is the main enzyme responsible for the formation of raltegravir-glucuronide. Thus, the data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation.

---

Biological Half-Life
9 hours
The apparent terminal half-life of raltegravir is approximately 9 hours, with a shorter alpha-phase half-life (approximetly1 hour) accounting for much of the AUC.

---

Raltegravir (MK-0518) has an oral bioavailability of 31% in humans when administered with food [3]
Raltegravir (MK-0518) reaches peak plasma concentrations (Cmax) of 1.5 μg/mL at a Tmax of 1 h after oral administration of 400 mg with food [3]
The area under the plasma concentration-time curve (AUC0–24h) of Raltegravir (MK-0518) in humans is 3.3 μg·h/mL at 400 mg twice daily [3]
Raltegravir (MK-0518) has a volume of distribution (Vd) of 11.8 L in humans [3]
The plasma elimination half-life (t1/2) of Raltegravir (MK-0518) in humans is 9 hours [3]
Raltegravir (MK-0518) is metabolized primarily by uridine diphosphate glucuronosyltransferase (UGT1A1) in the liver [3]
Renal excretion accounts for < 7% of the administered dose of Raltegravir (MK-0518) in humans [3]

Hepatotoxicity
In large clinical trials, therapy with raltegravir was associated with alanine aminotransferase (ALT) elevations in up to 10% and elevations of greater than 5 times the upper limit of normal (ULN) in 3% to 4% of patients, but these rates were similar to those in comparator groups receiving matched background optimized antiretroviral therapy without raltegravir. These elevations were not associated with clinical symptoms and generally did not require dose modification. There have been no published reports of clinically apparent cases of liver injury attributed to raltegravir. Nevertheless, the product label for raltegravir mentions hepatitis and hepatic failure as a potential adverse reactions, but without specific details. Raltegravir has also been linked to instances of Stevens Johnson syndrome and drug hypersensitivity reactions, which can be accompanied by hepatic involvement. Finally, initiation of antiretroviral therapy with raltegravir can result in the immune reconstitution syndrome which may cause a worsening or flare of an accompanying chronic hepatitis B or C in coinfected individuals.
Likelihood score: E (unproven but suspected cause of clinically apparent liver injury).

---

Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Limited information indicates that maternal doses of up to 1200 mg daily of raltegravir produce low levels in milk and would not be expected to cause any adverse effects in breastfed infants. Achieving and maintaining viral suppression with antiretroviral therapy decreases breastfeeding transmission risk to less than 1%, but not zero. Individuals with HIV who are on antiretroviral therapy with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision. If a viral load is not suppressed, banked pasteurized donor milk or formula is recommended.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.

---

Protein Binding
83%

---

Interactions
Pharmacokinetic interaction with omeprazole (substantially increased raltegravir peak plasma concentrations and area under the concentration-time curve (AUC)).
Pharmacokinetic interaction with rifabutin (increased raltegravir peak plasma concentrations and AUC).
Pharmacokinetic interaction with rifampin (decreased raltegravir plasma concentrations and AUC); rifampin is a strong inducer of UGT 1A1. If raltegravir is used in adults receiving rifampin, dosage of raltegravir film-coated tablets should be increased ... twice daily and patients monitored closely for virologic response.
Concomitant use of raltegravir and rifapentine is not recommended. HIV-infected tuberculosis patients treated with rifapentine have a higher rate of tuberculosis relapse than those treated with other rifamycin-based tuberculosis regimens; an alternative antimycobacterial agent is recommended in HIV-infected patients.
For more Interactions (Complete) data for Raltegravir (17 total), please visit the HSDB record page.

---

Raltegravir (MK-0518) shows low cytotoxicity in human PBMCs and CEMx174 cells, with CC50 values > 50 μM [3][6]
In humans, the most common adverse events of Raltegravir (MK-0518) (400 mg twice daily) are diarrhea (16%), nausea (13%), and headache (12%); grade 3–4 toxicities occur in < 3% of patients [3]
Raltegravir (MK-0518) has a plasma protein binding rate of 83% in humans [3]
Raltegravir (MK-0518) does not inhibit cytochrome P450 enzymes, resulting in minimal drug-drug interactions [3]
The oral LD50 of Raltegravir (MK-0518) in mice is > 2000 mg/kg [3]

[1]. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62.

[2]. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692.

[3]. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9.

[4]. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6.

[5]. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72.

[6]. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21.

Raltegravir is a pyrimidone that is pyrimidin-4(3H)-one in which the hydrogens at positions 2, 3, 5 and 6 are replaced by 2-[(5-methyl-1,3,4-oxadiazole-2-carbonyl)amino]propan-2-yl, methyl, hydroxy, and N-[(4-fluorophenyl)methyl]aminoacyl groups, respectively. It is an antiretroviral drug used for treatment of HIV infection. It has a role as an antiviral drug and a HIV-1 integrase inhibitor. It is a 1,2,4-oxadiazole, a dicarboxylic acid amide, a member of monofluorobenzenes, a pyrimidone, a hydroxypyrimidine and a secondary carboxamide.
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Raltegravir is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of raltegravir is as a HIV Integrase Inhibitor.
Raltegravir is an integrase inhibitor, the first of the class of antiviral agents active against the human immunodeficiency virus (HIV) that targets the viral integrase. Raltegravir is used in combination with other antiretroviral agents in the treatment of HIV infection. Raltegravir has not been linked convincingly to serum aminotransferase elevations during therapy or to episodes of acute, clinically apparent liver injury.
Raltegravir has been reported in Stachybotrys chartarum with data available.
Raltegravir is a small molecule with activity against human immunodeficiency virus (HIV). Raltegravir is an integrase inhibitor that blocks the integration of the viral genome into the host DNA, a critical step in the pathogenesis of HIV.
A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.
See also: Raltegravir Potassium (has salt form).

---

Drug Indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
FDA Label
Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection.
Treatment of human immunodeficiency virus (HIV-1) infection

---

Mechanism of Action
Raltegravir inhibits HIV integrase to prevent the viral genome being incorporated into the human genome. Raltegravir is primarily metabolized by glucuronidation.
Raltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the covalent insertion, or integration, of unintegrated linear HIV-1 DNA into the host cell genome preventing the formation of the HIV-1 provirus. The provirus is required to direct the production of progeny virus, so inhibiting integration prevents propagation of the viral infection. Raltegravir did not significantly inhibit human phosphoryltransferases including DNA polymerases alpha, beta, and gamma.

---

Therapeutic Uses
Pyrrolidinones
ISENTRESS (raltegravir) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. /Included in US product label/
ISENTRESS (raltegravir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in children and adolescents 2 years of age and older and weighing at least 10 kg. /Included in US product label/
/EXPERIMENTAL THER/ /Investigators/ describe five patients with HIV-2 infection (four antiretroviral-experienced and one antiretroviral-naive) treated with a regimen containing raltegravir. All responded to treatment as demonstrated by viral load and CD4(+) T-cell count monitoring. /This/ series confirms the clinical effectiveness of raltegravir in HIV-2-infected patients when given with other antiretrovirals to which the virus is susceptible.
/EXPERIMENTALTHER VET/ Feline leukemia virus (FeLV) is a gammaretrovirus that is a significant cause of neoplastic-related disorders affecting cats worldwide. Treatment options for FeLV are limited, associated with serious side effects, and can be cost-prohibitive. The development of drugs used to treat a related retrovirus, human immunodeficiency virus type 1 (HIV-1), has been rapid, leading to the approval of five drug classes. Although structural differences affect the susceptibility of gammaretroviruses to anti-HIV drugs, the similarities in mechanism of replication suggest that some anti-HIV-1 drugs may also inhibit FeLV. This study demonstrates the anti-FeLV activity of four drugs approved by the US FDA (Food and Drug Administration) at non-toxic concentrations. Of these, tenofovir and raltegravir are anti-HIV-1 drugs, while decitabine and gemcitabine are approved to treat myelodysplastic syndromes and pancreatic cancer, respectively, but also have anti-HIV-1 activity in cell culture. Our results indicate that these drugs may be useful for FeLV treatment and should be investigated for mechanism of action and suitability for veterinary use.

---

Drug Warnings
Severe, potentially life-threatening skin reactions have been reported, including some fatalities. Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction (including hepatic failure) have occurred.
Raltegravir and any other suspect agents should be discontinued immediately if signs or symptoms of severe skin or hypersensitivity reactions occur, including (but not limited to) severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, or angioedema. Clinical status, including liver aminotransferases, should be monitored and appropriate therapy initiated. A life-threatening reaction could occur if there is a delay in discontinuing raltegravir or other suspect agents after the onset of severe rash.
During initial treatment, patients who respond to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Mycobacterium avium, M. tuberculosis, cytomegalovirus (CMV), Pneumocystis jiroveci (formerly P. carinii), varicella-zoster virus (VZV)); this may necessitate further evaluation and treatment. Autoimmune disorders (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome) have been reported to occur in the setting of immune reconstitution; the time to onset is more variable and can occur many months after initiation of antiretroviral therapy.
Individuals with phenylketonuria (i.e., homozygous genetic deficiency of phenylalanine hydroxylase) and other individuals who must restrict their intake of phenylalanine should be advised that raltegravir chewable tablets contain aspartame (NutraSweet), which is metabolized in the GI tract to phenylalanine. Each 25-mg chewable tablet provides approximately 0.05 mg of phenylalanine and each 100-mg chewable tablet provides approximately 0.1 mg of phenylalanine.
For more Drug Warnings (Complete) data for Raltegravir (12 total), please visit the HSDB record page.

---

Raltegravir (MK-0518) is the first approved HIV-1 integrase strand transfer inhibitor (INSTI) for the treatment of HIV-1 infection [3]
Raltegravir (MK-0518) exerts its antiviral effect by binding to the HIV-1 integrase catalytic core, blocking the strand transfer step of viral DNA integration into the host cell genome [1]
Raltegravir (MK-0518) is indicated for the treatment of HIV-1 infection in adults and children aged ≥ 2 years, both as initial therapy and in treatment-experienced patients with resistance to other antiretroviral classes [3]
Raltegravir (MK-0518) demonstrates efficacy in simian AIDS models, providing a basis for studying lentiviral persistence during antiretroviral therapy [6]
Raltegravir (MK-0518) was approved by the FDA in 2007 [3]

C20H21FN6O5

444.42

444.155

518048-05-0

Raltegravir potassium;871038-72-1;Raltegravir sodium;1292804-07-9;Raltegravir-d4;2712343-38-7

54671008

White to off-white solid powder

1.5±0.1 g/cm3

1.651

-0.68

152.24

3

9

6

32

836

0

CZFFBEXEKNGXKS-UHFFFAOYSA-N

InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)

N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide

MK-0518; MK0518; MK 0518; MK-0518; Raltegravir; trade name: Isentress

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

注意： 本产品在运输和储存过程中需避光。

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

配方 1 中的溶解度: ≥ 2.5 mg/mL (5.63 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

---

配方 2 中的溶解度: ≥ 2.5 mg/mL (5.63 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

---

View More

配方 3 中的溶解度: ≥ 2.5 mg/mL (5.63 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液添加到 900 μL 玉米油中并混合均匀。

---

配方 4 中的溶解度: 30% PEG400+0.5% Tween80+5% Propylene glycol : 30 mg/mL

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。